文献类型：期刊文献

英文题名：The Roles of Reduced Folate Carrier-1 (RFC1) A80G (rs1051266) Polymorphism in Congenital Heart Disease: A Meta-Analysis

作者：Yi, Kang[1,2];Ma, Yu-Hu[2,3];Wang, Wei[2,3];Zhang, Xin[2,4];Gao, Jie[2,3];He, Shao-E[2,5];Xu, Xiao-Min[2,3];Ji, Meng[2,3];Guo, Wen-Fen[6];You, Tao[1,2]

第一作者：Yi, Kang

通信作者：You, T[1];You, T[2];Guo, WF[3]

机构：[1]Gansu Prov Hosp, Dept Cardiovasc Surg, Lanzhou, Gansu, Peoples R China;[2]Gansu Prov Int Sci & Technol Cooperat Base, Congenital Heart Dis Diag & Treatment, Lanzhou, Gansu, Peoples R China;[3]Lanzhou Univ, Clin Med Coll 1, Lanzhou, Gansu, Peoples R China;[4]Gansu Univ Chinese Med, Lanzhou, Gansu, Peoples R China;[5]Lanzhou Univ, Clin Med Coll 2, Lanzhou, Gansu, Peoples R China;[6]Baiyin Third Peoples Hosp, Dept Cardiol, Baiyin, Gansu, Peoples R China

第一机构：Gansu Prov Hosp, Dept Cardiovasc Surg, Lanzhou, Gansu, Peoples R China

通信机构：[1]corresponding author), Gansu Prov Hosp, Dept Cardiovasc Surg, Lanzhou, Gansu, Peoples R China;[2]corresponding author), Gansu Prov Int Sci & Technol Cooperat Base, Congenital Heart Dis Diag & Treatment, Lanzhou, Gansu, Peoples R China;[3]corresponding author), Baiyin Third Peoples Hosp, Dept Cardiol, Baiyin, Gansu, Peoples R China.

年份：2021

卷号：27

外文期刊名：MEDICAL SCIENCE MONITOR

收录：;Scopus(收录号：2-s2.0-85102708917);WOS:【SCI-EXPANDED(收录号:WOS:000647609100001)】；

基金：Health Industry Scientific Research Project of Gansu Province (GSWSKY2016-04)

语种：英文

外文关键词：Heart Defects, Congenital; Meta-Analysis; Polymorphism, Single Nucleotide; Reduced Folate Carrier Protein; Review

摘要：Background: We performed the present study to better elucidate the correlation of reduced folate carrier-1 (RFC1) A80G (rs1051266) polymorphism with the risk of congenital heart disease (CHD). Material/Methods: According to the designed search strategy, a systematic literature search was performed through the PubMed, Cochrane Library, Web of Science, EMBASE, CNKI, VIP, and Wan Fang databases to collect published case-control studies on the correlation between RFC1 A80G polymorphism and CHD. All relevant studies up to October 1, 2019 were identified. The odds ratio (OR) and 95% confidence interval (CI) of the genotype distribution were used as the effect indicators. Results: A total of 6 eligible studies was finally included in our meta-analysis, including 724 children with CHD, 760 healthy children, 258 mothers of the children with CHD, and 334 mothers of healthy control children. The meta-analysis revealed that for fetal analysis, only in the heterozygous model (GA vs GG, OR=1.36, 95% CI [1.06, 1.75], P=0.02) was RFC1 A80G polymorphism associated with risk of CHD. In maternal analysis, 3 genetic models of RFC1 A80G polymorphism increased the risk of CHD: the allelic model (A vs G, OR=1.36, 95% CI [1.07, 1.71], P=0.01), the homozygote model (AA vs GG, OR=2.99, 95%CI [1.06, 8.41], P=0.04), and the dominance model (GA+AA vs GG, OR=1.53, 95%CI [1.08, 2.16], P=0.02). Conclusions: The maternal RFC1 A80G polymorphism has a strong correlation with CHD. Compared with the G allele, the A allele increases the risk of CHD by 0.36-fold.